niacinamide has been researched along with arachidonyl-2-chloroethylamide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Conn, PJ; Kiritoshi, T; Lindsley, CW; Neugebauer, V; Ren, W; Stauffer, SR; Sun, H | 1 |
| Ji, G; Neugebauer, V | 1 |
2 other study(ies) available for niacinamide and arachidonyl-2-chloroethylamide
| Article | Year |
|---|---|
Modulation of pyramidal cell output in the medial prefrontal cortex by mGluR5 interacting with CB1.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Glycine; Inhibitory Postsynaptic Potentials; Male; Morpholines; Neural Inhibition; Niacinamide; Phenylacetates; Prefrontal Cortex; Pyramidal Cells; Pyrazoles; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Synaptic Transmission; Thiazoles | 2013 |
CB1 augments mGluR5 function in medial prefrontal cortical neurons to inhibit amygdala hyperactivity in an arthritis pain model.
Topics: Amygdala; Animals; Arachidonic Acids; Arthritis, Experimental; Cannabinoid Receptor Agonists; Evoked Potentials; Male; Niacinamide; Pain; Prefrontal Cortex; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5 | 2014 |